Overview

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Status:
Active, not recruiting

Trial end date:
2022-12-16

Target enrollment:

Participant gender:

Summary

An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Azacitidine